|
Faculty
|
|
BVSc; Massey University, New Zealand; 1984
PhD; University of California, Davis; 1993
Dendritic cell biology and therapy; primate models of infectious disease
Our research focuses on the immunology of infectious diseases, with the ultimate goal of exploiting the immune system for improved vaccination and disease control. A lot of our work focuses on dendritic cells (DC), which are critical in the initiation of immune responses to pathogens. The animal model we primarily study is the simian model of human immunodeficiency virus infection, being simian immunodeficiency virus or SIV, although we do basic immunology work using human cells. There are three major lines of investigation currently ongoing in the lab.
Dendritic cell biology in healthy and SIV-infected rhesus macaques: Studies in the human show that the two main subsets of DC, myeloid DC and plasmacytoid DC, are lost from the circulation in individuals with HIV infection associated with progression to disease. We have characterized DC subsets in blood and lymphoid tissues of healthy rhesus macaques and macaques with SIV infection. We have found that mDC and pDC are lost from blood in monkeys with AIDS, as in humans with HIV infection, and are also depleted from lymph nodes and spleen in these animals. This suggests that DC are not recruited to lymphoid tissues in progressive disease but rather undergo a systemic depletion. We are currently investigating the mechanism of this loss. We are also moving into the acute infection model and will evaluate DC dynamics in monkeys with acute SIV infection.
Dendritic cell- and vector-based immunotherapy: There is a lot of interest in using DC as antigen-presenting cells to deliver viral or tumor-associated antigens to T cells in immunotherapy. We have developed an mRNA approach to transfect monkey and human DC with viral antigens and have demonstrated that nucleofection with mRNA is a superior method for introducing transgenes into primary DC lines and for subsequent stimulation of virus-specific T cells. Adenoviral vectors are also potent vehicles for transducing DC and have been used to great effect as vaccines when given directly to monkeys or human volunteers. We have used recombinant adenoviral vectors as vaccines for SIV infection and for highly pathogenic avian influenza virus infection. Currently we are using adenovirus-5 and 35-based vectors in combination as an immunotherapy for monkeys that are infected with SIV and treated with antiretroviral drugs to control virus load.
Dendritic cell capture of cell-associated antigens
We have studied the interaction of DC with other cells and have shown that DC capture antigens from living cells and cross-present peptides from these antigens to cytotoxic T cells, a process known as ‘nibbling’. Work in the lab is currently looking at how the different sources of cellular antigens – from live cells or apoptotic cells – affects the process and efficiency of antigen capture. These studies involve confocal and live-cell imaging assays in collaboration with the Center for Biologic Imaging.

L-R: Nicole Banichar, Adam Soloff, Nada Melhem (graduated September 2007), Sherrianne Gleason, Kevin Brown, Xiangdong Liu, Viskam Wijewardana
Nicole Banichar, Veterinary Technician (Research III)
Primate Facility for Infectious Disease Research; nib12@pitt.edu
Xiang Dong Liu, Research Specialist III
BST3, 9th floor, Room 9053; 412-383-9057; xil37@pitt.edu
Viskam Wijewardana, BVSc, PhD
BST3, 9th floor, Room 9053; 412-383-9057; viskam@cvr.pitt.edu
Kevin Brown; Graduate Student Researcher
BST3, 9th floor, Room 9053; 412-383-9057; knbidm@pitt.edu
Sherrianne Gleason; Graduate Student Researcher
BST3, 9th floor, Room 9053; 412-383-9057; smg55@pitt.edu
Adam Soloff; Graduate Student Researcher
BST3, 9th floor, Room 9053; 412-383-9057; adamsoloff@hotmail.com
Last Updated: November 14, 2007
| Home | Top of Page |
Pitt Home | Find People | Contact Us |